Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1411 to 1425 of 1454 results for ages

  1. Updated pneumonia guidelines for babies and children with mild pneumonia

    Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.

  2. New drug approved for inherited clotting disorder, offering simpler dosing and enhanced quality of life.

    NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

  3. Hypertension: brief intervention to increase physical activity (IND96)

    This indicator covers the percentage of patients with hypertension aged 16 or over and who have not attained the age of 75 who score ‘less than active’ on GPPAQ in the preceding 15 months, who also have a record of a brief intervention in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM37

  4. Bipolar, schizophrenia and other psychoses: cervical screening (IND85)

    This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20

  5. Contraception: advice for people with diabetes (IND116)

    This indicator covers the percentage of women with diabetes aged 17 or over and who have not attained the age of 45 who have a record of being given information and advice about pregnancy or conception or contraception tailored to their pregnancy and contraceptive intentions recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM70

  6. Immunisation: rotavirus (24 weeks) (IND224)

    This indicator covers the percentage of babies who reached 24 weeks old in the preceding 12 months, who have received 2 doses of rotavirus vaccine before the age of 24 weeks. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM206

  7. Immunisation: DTaP (8 months) (IND215)

    This indicator covers the percentage of babies who reached 8 months old in the preceding 12 months, who have received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM197

  8. Bipolar, schizophrenia and other psychoses: cervical screening (50 to 64 years) (IND214)

    This indicator covers the percentage of women aged 50 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM196

  9. Bipolar, schizophrenia and other psychoses: cervical screening (25 to 49 years) (IND213)

    This indicator covers the percentage of women aged 25 or over and who have not attained the age of 50 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 3 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM195

  10. Tributes paid following the death of founding NICE chairman Professor Sir Mike Rawlins

    Founding chairman led NICE from 1999 to 2013, through its early years to its current position as a world leader in health and social care guidance and medicine evaluation.

  11. People with an acute respiratory infection offered monitoring from home

    People with an acute respiratory infection (ARI) could be monitored from their own homes using technology platforms that will feedback vital information on their condition to clinical staff

  12. Ground-breaking CAR-T therapy to treat aggressive form of blood cancer approved

    More than 400 people set to benefit after NICE recommends first personalised immunotherapy for lymphoma.

  13. Thousands could benefit from treatment for severe alopecia

    New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE

  14. NICE announces Dr Samantha Roberts as new Chief Executive

    NICE Chairman, Sharmila Nebhrajani, today announced Dr Samantha Roberts as incoming Chief Executive.

  15. Self-harm is everyone's business, NICE says in new draft guideline

    All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.